Table 2.
Clinical study: patients’ characteristics.
| Characteristics | Median | Range |
|---|---|---|
| Age (years) | 52.00 | 46.00, 61.00 |
| Weight (kg) | 67.50 | 57.50, 75.00 |
| BMI (kg/m2) | 23.30 | 20.53, 25.36 |
| POD (day) | 23.00 | 19.00, 29.00 |
| Tacrolimus daily dose (mg) | 5.00 | 4.00,6.00 |
| RBC (T/L) | 3.46 | 3.12, 3.93 |
| WBC (T/L) | 10.69 | 9.13, 13.19 |
| HGB (g/L) | 103.25 | 95.26, 115.46 |
| HCT (%) | 31.98 | 29.72, 34.96 |
| ALT (U/L) | 27.56 | 17.37, 39.49 |
| AST (U/L) | 19.24 | 15.92, 23.62 |
| ALP (U/L) | 79.18 | 62.16, 104.62 |
| LDH (U/L) | 353.72 | 294.90, 475.11 |
| CK (U/L) | 76.20 | 50.78, 105.43 |
| ALB (g/L) | 36.74 | 34.48, 38.68 |
| APTT (s) | 29.45 | 28.23, 31.56 |
| PT (s) | 13.00 | 12.51, 13.60 |
| TT (s) | 17.55 | 17.01, 18.14 |
| INR | 1.14 | 1.09, 1.20 |
| TBIL (μmol/L) | 15.90 | 12.13, 21.10 |
| BUN (μmol/L) | 10.70 | 9.19, 15.45 |
| SCR (μmol/L) | 86.65 | 70.94, 128.53 |
| Glucose (μmol/L) | 6.61 | 5.91, 7.96 |
| Recipient Genotype | Count (Percentage) | p-value |
| CYP3A5*3 (rs776746) | 0.33 | |
| CC | 38 (44.2%) | |
| CT | 45 (52.3%) | |
| TT | 3 (3.5%) | |
| CYP3A4*18B (rs2242480) | 0.30 | |
| CC | 45 (52.3%) | |
| CT | 40 (46.5%) | |
| TT | 1 (1.2%) | |
| IL-10 (rs1800896) | 0.20 | |
| TT | 63 (73.3%) | |
| CT | 23 (26.7%) |
BMI: body mass index; POD: postoperative days; RBC: red blood cell count; WBC: white blood cell count; HGB: hemoglobin; HCT: hematocrit; ALT: alanine transaminase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; CK: phosphocreatine kinase; ALB: albumin concentration; APTT: activated partial thromboplastin time; PT: prothrombin time; TT: thrombin time; INR: international normalized ratio; TBIL: total bilirubin; BUN: blood uric nitrogen; SCR: serum creatinine.